Biomarker Discovery In Clinical Research
What is this
This trend focuses on the discovery and validation of biomarkers in clinical research, which are critical for early disease detection and personalized medicine. It encompasses various research signals including lipid levels, electron microscopy in tissue analysis, and novel enzyme activity studies.
Why it matters
Biomarkers are fundamental in enhancing diagnostic precision and tailoring treatments to individual patient profiles, fueling the growth of precision medicine. With the healthcare industry shifting towards personalized care, robust biomarker discovery is a key catalyst for innovative therapeutic strategies.
Investment angle
Investors can consider backing companies specializing in diagnostic tools, genomic sequencing, and personalized medicine platforms. Firms like Illumina, Guardant Health, and other biotech startups focusing on biomarker discovery represent potential investment targets, complemented by relevant biotech ETFs.
A promising, steady-growth sector in personalized medicine with manageable risks for long-term investors. Investability: 7/10.
History
| date | signals | new | substance |
|---|---|---|---|
| 2026-03-12 | 12 | 100% | |
| 2026-03-22 | 34 | +22 | 100% |
| 2026-04-02 | 37 | +3 | 100% |
| 2026-04-13 | 40 | +3 | 98% |
| 2026-04-24 | 42 | +2 | 98% |
| 2026-05-04 | 44 | +2 | 98% |
| 2026-05-16 | 48 | +4 | 98% |
| 2026-05-27 | 48 | +0 | 98% |
| 2026-06-06 | 48 | +0 | 98% |
| 2026-06-16 | 51 | +3 | 98% |
| 2026-06-27 | 54 | +3 | 98% |
| 2026-07-07 | 55 | +1 | 98% |
| 2026-07-18 | 57 | +2 | 98% |
| 2026-07-28 | 62 | +5 | 98% |
Evidence
- 2026-07-27ClinicalTrials.gov[PHASE2] A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus · detail
- 2026-07-24ClinicalTrials.gov[PHASE2] A Randomized Clinical Trial Evaluating the Efficacy of Clinical Pharmacist Assistance Along With Pharmaceutical and Non-pharmaceutical Therapy in the Early Rheumatoid Arthritis · detail
- 2026-07-24ClinicalTrials.gov[] Multicenter Validation of the 2025 Classification Criteria for Axial Spondyloarthritis · detail
- 2026-07-22PubMedANCA-associated vasculitis: From immunopathogenesis to diagnosis and toward precision therapy. · detail
- 2026-07-20ClinicalTrials.gov[PHASE2] Umbilical Cord Mesenchymal Stromal Cell Secretome for Moderate Rheumatoid Arthritis: A Randomized Double-Blind Placebo-Controlled Trial · detail
- 2026-07-12NIH RePORTERAssociation of Phenotypes and Genotype with Treatment Response in Psoriatic Arthritis · detail
- 2026-07-08PubMedInflammaging and osteoarthritis - therapeutic opportunities. · detail
- 2026-06-30ClinicalTrials.gov[PHASE1] Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis · detail
- 2026-06-25Seeking Alpha RSSCynata Therapeutics Limited (CYYNF) Discusses Phase II Acute Graft Versus Host Disease and Phase III Osteoarthritis Trial Results - Slideshow · detail
- 2026-06-24PubMedThe evolving landscape of osteoarthritis management: From conventional pharmacotherapy to gene therapy, stem cell therapy and nanotechnology-based therapeutics. · detail
- 2026-06-22Seeking Alpha RSSCynata Therapeutics Limited (CYYNF) Discusses Phase II Acute Graft Versus Host Disease and Phase III Osteoarthritis Trial Results Transcript · detail
- 2026-06-16PubMed[Efficacy and safety of fourth-generation CAR-T cells targeting CD19 and BCMA with anti-IL-6 antibody secretion in refractory systemic lupus erythematosus]. · detail
- 2026-06-12ClinicalTrials.gov[] Individualizing Anti-TNF Therapy in Patients With Inflammatory Bowel Disease · detail
- 2026-06-12PubMedChimeric antigen receptor T-cell therapy in rheumatoid arthritis. · detail
- 2026-05-14ClinicalTrials.gov[PHASE1] A Study of IN026 in Participants With Refractory Gout · detail
- 2026-05-13PubMedHuman Neutrophil Elastase and the Protein-Storm Axis: Reversible Synthetic Inhibitors in Inflammatory Disease. · detail
- 2026-05-12ClinicalTrials.gov[PHASE2] Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases · detail
- 2026-05-07ClinicalTrials.gov[] Rheumatoid Arthritis Remission Screening and Prospective Surveillance · detail
- 2026-04-28PubMedTargeting NAV2-mediated Wnt/β-catenin signaling in rheumatoid arthritis: current evidence and emerging therapeutic approaches. · detail
- 2026-04-28ClinicalTrials.gov[PHASE1] A Study to Test How Well BI 3000202 is Tolerated by People With Type 1 Interferonopathies · detail